BioCentury
ARTICLE | Company News

Dermavant, NovaQuest in milestone deal for tapinarof

August 31, 2018 6:58 PM UTC

The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) received the $100 million investment from NovaQuest Capital Management in exchange for milestone payments related to tapinarof. The aryl hydrocarbon receptor (AHR) modulator has completed Phase II trials to treat psoriasis and atopic dermatitis...

BCIQ Company Profiles

Roivant Sciences Ltd.